AstraZeneca's T2D Drug BYDUREON BCise Gets Approval In US To Treat Pediatric Patients

AstraZeneca PLC (AZN) on Friday said its BYDUREON BCise has been approved by the Food and Drug Administration to treat type 2 diabetes (T2D) in pediatric patients aged more than 10 years.

The drug is indicated as an adjunct to diet and exercise for improving glycemic control in pediatric patients with T2D.

BYDUREON BCise is the first once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment option for pediatric patients with T2D in the US, the company said.

BYDUREON BCise was approved in the US in 2017 and in the EU in 2018 for the treatment of adults with T2D.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT